These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10894873)

  • 21. Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.
    Piccart MJ; Gore M; Ten Bokkel Huinink W; Van Oosterom A; Verweij J; Wanders J; Franklin H; Bayssas M; Kaye S
    J Natl Cancer Inst; 1995 May; 87(9):676-81. PubMed ID: 7752272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer.
    Francis P; Schneider J; Hann L; Balmaceda C; Barakat R; Phillips M; Hakes T
    J Clin Oncol; 1994 Nov; 12(11):2301-8. PubMed ID: 7964944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
    McCourt C; Dessie S; Bradley AM; Schwartz J; Brard L; Dizon DS
    Int J Gynecol Cancer; 2009 Apr; 19(3):343-7. PubMed ID: 19407557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Taxane-based palliative chemotherapy for metastatic breast cancer: matched pair analysis to compare the efficacy and safety of docetaxel and paclitaxel].
    Schneeweiss A; Lenz F; Beldermann F; Geberth M; Goerner R; Solomayer E; Bastert G
    Zentralbl Gynakol; 2001 Sep; 123(9):520-8. PubMed ID: 11709745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
    Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
    Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel in the treatment of ovarian cancer.
    Kavanagh JJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):73-81. PubMed ID: 12108900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
    Ota T; Takeshima N; Takizawa K
    Eur J Gynaecol Oncol; 2011; 32(5):471-5. PubMed ID: 22053655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
    Komiyama S; Tsuji H; Asai S; Dokoh J; Ishikawa M; Mikami M
    Eur J Gynaecol Oncol; 2005; 26(3):299-302. PubMed ID: 15991531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
    Chan S
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
    Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
    Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas.
    Matsuo K; Eno ML; Im DD; Rosenshein NB
    Arch Gynecol Obstet; 2010 Feb; 281(2):325-8. PubMed ID: 19455347
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
    Markman M; Brady MF; Spirtos NM; Hanjani P; Rubin SC
    J Clin Oncol; 1998 Aug; 16(8):2620-4. PubMed ID: 9704711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
    Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
    J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
    Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
    Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
    Valero V; Holmes FA; Walters RS; Theriault RL; Esparza L; Fraschini G; Fonseca GA; Bellet RE; Buzdar AU; Hortobagyi GN
    J Clin Oncol; 1995 Dec; 13(12):2886-94. PubMed ID: 8523051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel administered on a weekly basis for metastatic breast cancer.
    Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
    J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
    Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II trial of docetaxel in platinum pre-treated patients with advanced epithelial ovarian cancer: a Japanese cooperative study.
    Katsumata N; Tsunematsu R; Tanaka K; Terashima Y; Ogita S; Hoshiai H; Kohno I; Hirabayashi K; Yakushiji M; Noda K; Taguchi T
    Ann Oncol; 2000 Dec; 11(12):1531-6. PubMed ID: 11205459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.